Why Eli Lilly Stock Topped the Market Today

Although mighty American pharmaceutical company Eli Lilly (NYSE: LLY) has a dizzying number of commercialized products, it's a recently approved medication that's attracted outsized attention lately. This is its GLP-1 weight-loss drug, Zepbound. On Friday, thanks to news of a large Federal subsidy program apparently in the works, shares of the drug's maker leaped more than 3% higher in value.That morning The Washington Post, citing official documents it had obtained from the Centers for Medicare and Medicaid Services (CMS), provided details of that program. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool